Osteonecrosis of the jaw associated with pamidronate therapy

@article{Zarychanski2006OsteonecrosisOT,
  title={Osteonecrosis of the jaw associated with pamidronate therapy},
  author={Ryan Zarychanski and Erin Elphee and P Walton and James B. Johnston},
  journal={American Journal of Hematology},
  year={2006},
  volume={81}
}
Bisphosphonates are commonly used in the treatment and prevention of osteoporosis, and they are also an important therapeutic adjunct in multiple myeloma and other cancers metastatic to bone. Bisphosphonates are generally well tolerated and associated with minimal adverse effects; however, there exists a growing concern that intravenous bisphosphonate use is associated with osteonecrosis of the jaw (ONJ). We report the occurrence of osteonecrosis of the jaw associated with pamidronate therapy… 
Osteonecrosis of the myeloma patients treated with bisphosphonates.
  • S. Capalbo, M. Franzese, G. Palumbo
  • Medicine
    Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
  • 2007
TLDR
There was no significant association between the occurrence of ONJ and the presence of osteolytic lesions, disease status and the use of thalidomide.
Bisphosphonate-Associated Osteonecrosis of the Jaw in Patients with Multiple Myeloma and Breast Cancer
TLDR
Hyperbaric oxygen, which has proven efficacious in other forms of osteonecrosis by establishing an oxygen gradient, is of no definitive benefit to patients with bisphosphonate-induced exposed bone.
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
TLDR
The authors' experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with ONJ, and 2 patients in whom primary surgical salvage was performed successfully for ONJ are described.
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
TLDR
Osteonecrosis of the jaws is strongly associated with the use of aminobisphosphonates, and the mechanism of disease is probably severe suppression of bone turnover, and possible mechanisms of etiopathogenesis are suggested.
Bisphosphonate Associated Osteonecrosis of the Jaw
TLDR
There is insufficient evidence to confirm a causal link between low-dose BP use in the osteoporosis patient population and ONJ, but BP associated ONJ is associated with high- dose BP therapy primarily in the oncology patient population.
Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare
TLDR
It is important for the reconstructive head and neck surgeon to recognize the clinical presentation of bisphosphonate-induced osteoradionecrosis of the jaw and the role of conservative management in consistently achieving good results.
A survey of bisphosphonate-related osteomyelitis/osteonecrosis of the jaws
TLDR
Patients with bisphosphonate-related osteomyelitis and osteonecrosis of the jaws in Japan were studied and 8 of the patients were completely cured, while 17 patients remained under treatment at the time of this writing.
Bisphosphonate-associated osteomyelitis of the jaw: guidelines for practicing clinicians.
  • S. Wimalawansa
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2008
TLDR
Current evidence supports an infectious and perhaps immunologic underlying cause for BAOMJ and the benefits of bisphosphonates far outweigh the risks.
Osteonecrosis of the jaw related to the use of bisphosphonates
TLDR
Osteonecrosis of the jaw is a distinct entity of uncertain origin that is increasingly being observed in patients treated with potent aminobisphosphonates, although the etiology is probably multifactorial.
...
1
2
3
4
5
...

References

SHOWING 1-6 OF 6 REFERENCES
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.
Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation with Aredia® and Zometa® Use.
TLDR
The new entity of osteonecrosis of the jaws in myeloma patients is most strongly associated with use of Aredia and/or Zometa, and this risk is time-dependent and becomes significant at 12 months, increasing thereafter to 36 months.
Polymorphism of the MICA gene and risk for oral submucous fibrosis.
TLDR
The results suggest that allele A6 in MICA might confer a risk for OSF, and the SNP patterns suggest five distinct allelic patterns.
Bisphosphanates and oral cavity avascular bone necrosis.
  • C. Migliorati
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
Osteonecrosis of the jaws associated with cancer chemotherapy.
  • J. Wang, N. Goodger, M. Pogrel
  • Medicine
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2003
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
  • R. Marx
  • Medicine
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2003